ArticleJournal of cancer research and clinical oncology2018
Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients.
Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Prognostic factors of Takotsubo cardiomyopathy: a systematic review.ESC heart failure · 2021Pooled it
- Malignancy predicts outcome of Takotsubo syndrome: a systematic review and meta-analysis.Heart failure reviews · 2020Pooled it
- Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy.Heart failure reviews · 2019Pooled it
- Takotsubo syndrome in a cancer patient treated with a combination of anti-cancer drugs including immune checkpoint inhibitors: a case report.European heart journal. Case reports · 2024Article
- Machine Learning in Cardio-Oncology: New Insights from an Emerging Discipline.Reviews in cardiovascular medicine · 2023Review
- Review
- A contemporary update on cancer and takotsubo syndrome.Frontiers in cardiovascular medicine · 2023Review
- Clinical outcomes of takotsubo syndrome in patients with cancer: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2023Review
- Article
- Takotsubo syndrome and respiratory diseases: a systematic review.European heart journal open · 2022Review
- Takotsubo Syndrome: Translational Implications and Pathomechanisms.International journal of molecular sciences · 2022Review
- Cardiogenic shock among cancer patients.Frontiers in cardiovascular medicine · 2022Review
- Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type.ESC heart failure · 2021Article
- Cancer and Takotsubo syndrome: from rarity to clinical practice.ESC heart failure · 2021Article
- Interventional Strategies in Cancer-induced Cardiovascular Disease.Current oncology reports · 2021Review
- Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis.Journal of clinical medicine · 2021Article
- Takotsubo Cardiomyopathy: Current Treatment.Journal of clinical medicine · 2021Review
- Takotsubo syndrome: an overview of pathophysiology, diagnosis and treatment with emphasis on cancer patients.Heart failure reviews · 2019Review
- Is Transient Takotsubo Syndrome Associated With Cancer? Why, and With What Implications for Oncocardiology?Journal of the American Heart Association · 2019Article
- Takotsubo cardiomyopathy in cancer patients.Cardio-oncology (London, England) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced cardiomyopathy is a critical complication of treatment for cancer. The emotional stress of a cancer diagnosis, ongoing chemotherapy, abnormal cancer-related wasting syndrome may contribute to cardiac morbidity in these patients. The burden of Takotsubo Cardiomyopathy (TCM) in cancer patients is unknown. The incidence of TCM and related outcomes in cancer patients was investigated in this study.
methodsThe 2007-2013 National Inpatient Sample (NIS) was analyzed for patients with a prior and new diagnosis of TCM with and without malignancy. Risk factors for mortality were adjusted for associated conditions by multivariable logistic regression analysis.
resultsFrom 2007 to 2013, an estimated 122,855 adults were admitted with a diagnosis of TCM. In 2013, the incidence of admissions in US of patients with coexisting TCM and malignancy was 1.13%. Patients admitted for TCM with coexisting malignancy had a significantly higher mortality (13.8 vs. 2.9%, p < 0.0001), length of stay (7 vs. 4 days, p < 0.0001) and total charges ($29,291 vs. $36,231, p < 0.0001), compared to those with no malignancy. In patients with a primary diagnosis of TCM and without any underlying malignancy, males had a higher mortality (4.02 vs. 1.03%, p < 0.0001), whereas there was no gender difference in mortality in those with coexisting malignancy (6.25 vs. 6.45%, p = 0.965). On multivariable logistic regression analysis, risk factors associated with mortality were solid cancer (OR 3.43, p = 0.008), stroke (OR 18.33, p < 0.0001) and heart failure (OR 1.918, p = 0.004).
conclusionsOutcomes are significantly worse in patients with TCM and malignancy. Hence, this patient population must be regarded as high-risk and early diagnostic consideration for TCM is warranted. Early intervention may help lower mortality, decrease resource utilization and reduce the health care costs in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.